An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer

OBJECTIVES: Tyrosine kinase inhibitors (TKIs) are a standard care option in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. TKI-based combination treatment modes show encouraging outcomes. However, it remains unknown which is the optimal treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yuexiao, Xia, Xiaojun, Shao, Lihua, Guo, Liyun, Dong, Yumei, Tian, Jinhui, Xu, Lijun, Niu, Ruijun, Wei, Shihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376288/
https://www.ncbi.nlm.nih.gov/pubmed/35978809
http://dx.doi.org/10.3389/fonc.2022.616546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376288/
https://www.ncbi.nlm.nih.gov/pubmed/35978809
http://dx.doi.org/10.3389/fonc.2022.616546

Ejemplares similares